pharyngeal candidiasis, topical agents, including nystatin and clotrimazole troches, can be used for initial episodes, although patients with HIV infection are likely to experience relapse [4] . These medications are inconvenient to administer, require frequent applications, and are less effective than systemic therapies [5] [6] [7] . Systemic therapy with oral fluconazole or itraconazole usually is effective for treatment of oropharyngeal candidiasis [3, 4] . However, in vivo and in vitro emergence of Candida species resistant to fluconazole has been well documented [3, 4, [8] [9] [10] . The incidence of oropharyngeal or esophageal candidiasis due to fluconazole-resistant Candida species is speculated to be !5% [3, 4, 7] . Newer agents, such as voriconazole, caspofungin, and micafungin, have shown promising activity against mucocutaneous candidiasis [11] [12] [13] [14] [15] [16] [17] , but the need to administer caspofungin and micafungin intravenously limits their use.
Posaconazole is an extended-spectrum triazole with potent in vitro activity against Candida species (including fluconazoleresistant strains), Aspergillus, Cryptococcus, and many pathogenic molds, including Zygomycetes [18] [19] [20] [21] [22] . Posaconazole also has demonstrated in vitro activity against Candida species other than Candida albicans, such as Candida glabrata and Candida krusei [21] . In addition, there have been anecdotal reports of successful outcomes in patients with systemic candidiasis caused by C. glabrata and Candida tropicalis who could not tolerate or had disease refractory to other antifungal agents [23, 24] .
Preclinical in vitro studies have demonstrated that Candida species may be less likely to develop resistance to posaconazole than to other azoles. In C. albicans, posaconazole is a substrate of ATP-dependent efflux pumps encoded by CDR1 and CDR2 but not a substrate of major facilitator pumps encoded by MDR1 and FLU1 [25, 26] . These observations suggest that posaconazole may have clinical activity against azole-susceptible and azole-resistant Candida species.
The primary objective of this study was to evaluate the clinical efficacy of posaconazole in the treatment of oropharyngeal candidiasis in subjects with HIV infection, using fluconazole as the active comparator. Secondary objectives included evaluating mycological efficacy, safety, and clinical relapse.
MATERIALS AND METHODS

Subjects.
Subjects у18 years old were eligible for study participation if they met the following criteria: confirmed HIV infection; clinical evidence of pseudomembranous oropharyngeal candidiasis, defined as у2 discrete pseudomembranous plaques or a single confluent plaque of у3 cm; microbiological evidence of Candida species documented by either potassium hydroxide or fungal stain of specimens obtained via scraping or swabbing of oropharyngeal lesions and confirmed by mycological culture; anticipated survival of 12 months; ability to swallow study medication; and a Karnofsky performance score of у60 [27] .
Subjects were excluded if they had received any systemic antifungal therapy during the week before enrollment or used topical oral antifungal therapy within 2 days before enrollment, received other investigational agents in the preceding month, were intolerant of azole drugs, used protease inhibitors for the first time within 30 days before enrollment, or were taking medications that could interact with azoles. Medications excluded at enrollment were also prohibited during the 2-week treatment period. Additional exclusion criteria included chemotherapy-related oral mucositis, a platelet count of !75,000 platelets/mm 3 , a QTc interval prolonged by 110% of the normal interval, a history of treatment failure with fluconazole, or evidence of hepatic or renal disease (i.e., alanine aminotransferase, aspartate, or alkaline phosphatase concentrations 5 times the upper limit of a normal concentration; total bilirubin values 12.5 times the upper limit of a normal value; prothrombin time 15 s over the established control time or an international normalized ratio of у2; and serum creatinine concentrations 13 times the upper limit of a normal concentration).
Study design. This multicenter, randomized, evaluatorblinded clinical study compared the efficacy, tolerance, and safety of posaconazole with those of fluconazole. Each subject was randomly assigned to 1 of 2 parallel treatment arms. Subjects received 200 mg of either posaconazole or fluconazole oral suspension (40 mg/mL) on day 1, followed by 100 mg/day of the same drug for 13 days. All doses were self-administered. Subjects were instructed to swish and swallow the study drug, consume the medication with food or immediately after eating, and not rinse their mouth for at least 30 min after taking the study drug.
At the baseline visit, signs and symptoms of oropharyngeal candidiasis were assessed, and oropharyngeal lesions were swabbed or scraped to obtain specimens for fungal staining and culture. Signs and/or symptoms of oropharyngeal candidiasis and the severity of each were assessed using a rating system modified from an AIDS Clinical Trials Group protocol. The extent of lesions was evaluated using a scale of 0-3, in which a score of 0 indicated that the lesion was absent, a score of 1 indicated that the lesion was minimal (1-5 plaques and/or 1 confluent plaque of р3 cm), a score of 2 indicated that the lesion was diffuse (plaques with more than minimal extent), and a score of 3 indicated that the lesion had become worse (applied only to subjects with diffuse plaques at the previous visit). Severity of symptoms (pain, burning, and erythema) was also assessed using a scale of 0 to 3, in which a score of 0 indicated that no symptoms were present, a score of 1 indicated mild symptoms, a score of 2 indicated moderate symptoms, and a score of 3 indicated severe symptoms. Oropharyngeal specimens were stained using either a wet preparation consisting of 10% potassium hydroxide, a chlorazol black E fungal stain (Delasco), or a Gram stain and were examined for the presence of yeast, hyphae, or pseudohyphae that were consistent with Candida species. This was repeated on days 7 and 14 after the first dose if there was no improvement in symptoms.
Candida species in the oropharynx were quantitated using a swish-and-spit technique and reported in colony-forming units (cfu). Subjects rinsed their mouths with 10 mL of physiological saline and expelled the rinse into a sterile container. Specimens were then shipped to a reference laboratory for analysis. Specimen evaluation included mycological quantitative culture, identification of fungal genus and species, and in vitro anti- 23 (13) 22 (13) NOTE. Data are no. (%) of subjects. Treated subjects are those who were randomized and received a у1 dose of study drug.
a Includes subjects who were lost to follow-up, decided not to continue treatment, were noncompliant, or did not meet protocol eligibility requirements. b Includes subjects who did not begin follow-up, were lost to follow-up, were noncompliant with the protocol, or did not meet study entry criteria.
fungal susceptibility using National Committee for Clinical Laboratory Standards guidelines (M27-T). After the baseline visit, symptoms and severity of oropharyngeal candidiasis were assessed, and additional mycological cultures were performed on days 7, 14, and 42 (the follow-up period began 28 days after receipt of the last dose of study drug). Efficacy evaluations. The primary end point was the proportion of subjects who were clinically cured or showed improvement after 14 days of therapy. The efficacy of both regimens was assessed by comparison of clinical response rates and changes from baseline in signs and symptoms of oropharyngeal candidiasis (pain, burning, and erythema) and extent of oral lesions.
Clinical success was defined as cure (absence of plaques or ulcers and no or minimal symptoms) or improvement (partial resolution of pretreatment signs and symptoms of candidiasis; i.e., a decrease in scores used to measure lesions and symptoms) after 14 days of treatment. Therapy was considered to have failed if subjects had no improvement or if signs or symptoms worsened after у7 consecutive days of therapy and if evidence of Candida was demonstrated by fungal staining of specimens obtained from oropharyngeal lesions.
For subjects with cure or improvement on day 14 who had received у80% of their doses, durability of cure or improvement or clinical relapse (defined as recurrence of signs or symptoms after initial improvement or cure on day 14) was evaluated as a secondary end point on day 42. Other secondary end points included clinical response after 7 days of therapy and mycological response rate by visit, evaluated by quantitative mycological cultures performed on days 7 and 14. Mycological success was defined as a quantitative yeast culture yielding р20 cfu/mL of Candida species; eradication was defined as 0 cfu/ mL. Persistence (nonsuccess) was defined as 120 cfu/mL of Candida species. Relapse was defined as р20 cfu/mL of Candida species on day 14 and 120 cfu/mL on day 42.
Statistical methods. On the basis of the assumption that the common clinical cure or improvement rate was 85%, a sample size of 120 evaluable subjects per treatment arm was targeted for enrollment to ensure a 90% probability of achieving this criterion of equivalence. Analyzed data sets included data obtained from the following groups: the all-treated population, which was a subset of the intent-to-treat population (i.e., all randomized subjects) and comprised subjects who were randomized and received у1 dose of the study drug; the modified intent-to-treat population, which consisted of all subjects who were randomized, received у1 dose of study drug, and had positive results of culture for Candida species at baseline; and the protocol-evaluable population, which consisted of modified intent-to-treat subjects who received therapy for at least 7 consecutive days and had a clinical response assessment on day 14. Primary efficacy analysis was performed on the modified intent-to-treat data set, and confirmatory analyses were performed on the protocol-evaluable subset. Clinical response rate was assessed using a 95% CI (2-sided) for the difference in clinical cure or improvement rates between regimens and was constructed using the normal approximation of binomial distribution. Posaconazole was considered to be noninferior to fluconazole if the lower limit of the 95% CI for the difference in the corresponding response rates (posaconazole vs. fluconazole) exceeded a d of Ϫ15%, if the observed rate for fluconazole was 180% and exceeded a d of Ϫ20%, and if the observed rate for fluconazole was р80%.
Safety evaluations. A complete physical examination with assessment of vital signs, electrocardiography, and complete clinical laboratory testing (hematology, blood chemistry, and urinalysis) was performed at baseline. Safety evaluations, including assessment of vital signs, monitoring and recording of adverse events, and clinical laboratory testing, were performed on days 7, 14, and 42. CD4 + cells were counted at baseline or within 3 months after study initiation.
Adverse events were assessed and recorded at each visit; the investigator determined the severity and relationship of adverse events to the study drug. A serious adverse event was any event that was fatal, life-threatening, or significantly or permanently disabling; required hospitalization or prolonged the subject's hospitalization; or was a congenital anomaly or birth defect.
Before study initiation, a duly constituted independent ethics committee or institutional review board reviewed and approved the study protocol at each site. The study was performed in accordance with good clinical practice, guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, and the principles set forth in the World Medical Assembly Declaration of Helsinki. Each subject signed a written statement of informed consent before receiving any study medication.
RESULTS
Demographic Characteristics of Subjects and Treatment
The study was conducted from 15 December 1998 through 27 October 1999. A total of 366 subjects were enrolled at 47 sites, 19 of which were in the United States and 28 of which were located at other sites worldwide (primarily in Europe, Latin America, Canada, and South Africa). Sixteen subjects were randomized but did not receive a study drug. The remaining 350 patients formed the all-treated subset, of whom 178 received posaconazole and 172 received fluconazole. In this subset, baseline demographic characteristics were similar with respect to race, sex, and age (table 1). Mean and median CD4 + cell counts were similar in both treatment arms. Most subjects were not receiving antiretroviral therapy at baseline. No differences were noted between treatment groups for any disease severity indices for all study populations. Overall, 310 (89%) of the 350 alltreated subjects completed 14 days of therapy, and 291 (83%) completed follow-up (table 2) . Of the 350 subjects in the alltreated population, 329 were included in the modified intentto-treat subset (posaconazole, n p 169; fluconazole, n p 160), and 278 were included in the protocol-evaluable subset (posaconazole, n p 143; fluconazole, n p 135). 
Baseline Mycological Findings and Susceptibility Testing
Baseline mycological cultures revealed that C. albicans accounted for 92.3% and 90.2% of the isolates obtained from subjects in the posaconazole and fluconazole treatment groups, respectively (table 3). C. glabrata was the second most common Candida species isolated, accounting for 7.7% and 5.5% of isolates, respectively. Results of baseline susceptibility testing of Candida isolates are presented in table 3.
Efficacy Analysis
Clinical efficacy. Both posaconazole and fluconazole were highly effective in producing favorable outcomes in subjects with oropharyngeal candidiasis after 7 and 14 days of treatment. ), although the difference did P p .24 not reach statistical significance. Clinical outcomes (percentage responding) in the modified intent-to-treat group, according to in vitro susceptibility to fluconazole in the Candida isolates recovered at baseline, are shown in figure 2 .
Mycological efficacy. In the modified intent-to-treat subset, rates of mycological success and eradication on days 7 and 14 were similar for both treatment arms, with mycological success observed in 68% of both posaconazole recipients and fluconazole recipients on day 14. However, among subjects who com- 3 ). P p .084 Safety analyses. Subjects who received a least 1 dose of the study drug (all-treated subset) were included in the safety analysis. Most subjects (192%) received treatment for у11 days. During the treatment phase, 21 (12%) of 178 subjects in the posaconazole arm and 19 (11%) of 172 subjects in the fluconazole arm discontinued therapy. Reasons for discontinuation during acute-phase treatment were similar for both groups (table 2). Seven posaconazole recipients (4%) and 7 fluconazole recipients (4%) prematurely discontinued participation the study because of adverse events; however, a review of these adverse events revealed no consistent pattern. Five subjects died during acute treatment, during follow-up, or thereafter, 4 of whom were in the posaconazole group and 1 of whom was in the fluconazole group. Of the 4 deaths in the posaconazole group, only 1 occurred during acute treatment (suicide). No deaths were considered to be related to treatment. No significant changes in clinical laboratory parameters were observed in either group.
Overall, 114 (64%) of 178 posaconazole recipients reported treatment-emergent adverse events, compared with 117 (68%) of 172 fluconazole recipients (table 4). The incidence of treatment-related adverse events was similar between posaconazole and fluconazole treatment arms (25% vs. 24%); the most common adverse events were gastrointestinal and included nausea (6% in the posaconazole arm vs. 5% in the fluconazole arm), vomiting (4% vs. 1%), and diarrhea (2% vs. 3%). Serious adverse events were observed in 17 (10%) of 178 posaconazole recipients and 22 (13%) of 172 fluconazole recipients. Serious adverse events reported with the greatest frequency were diarrhea, tuberculosis, dehydration, fever, headache, anemia, neutropenia, and pancreatitis in the fluconazole group and fever, asthenia, abdominal pain, respiratory insufficiency, and lymphadenopathy in the posaconazole group. No serious adverse events were considered to be related to the study drug in the posaconazole group. However, 5 adverse events (increased serum glutamic-pyruvic transaminase levels in 1 subject and dehydration, diarrhea, acute gastroenteritis, and vomiting in 1 subject) were considered to be possibly related to fluconazole treatment.
DISCUSSION
The results of this study demonstrate that posaconazole was as effective as fluconazole in producing a successful clinical outcome in HIV-infected subjects with oropharyngeal candidiasis. Furthermore, posaconazole appears to be more effective than fluconazole in sustaining a successful clinical outcome and maintaining a symptom-free period after discontinuation of treatment. Fewer posaconazole recipients than fluconazole recipients had a clinical relapse on day 42, although the difference did not reach statistical significance. A similar trend was observed when the mycological outcome was assessed. Rates of mycological success were similar for the posaconazole and fluconazole arms after treatment for 7 and 14 days, but significantly more posaconazole recipients than fluconazole recipients continued to have mycological responses on day 42 (P p ). .038
As expected, not all subjects who demonstrated a successful clinical response also had a successful mycological response. In each treatment group, ∼92% of subjects had a successful clinical response after 14 days of treatment, but only 68% had a successful mycological response. This observation is not surprising, because many HIV-infected patients with mucosal candidiasis continue to harbor Candida species on mucosal surfaces, even after the infection has clinically resolved. Symptom relief is more important than complete eradication of Candida species from the mucosal surfaces. Furthermore, considering the continued immunosuppressed state of persons with HIV infection, it is not unexpected that 130% of subjects experienced clinical relapse and 150% of subjects experienced mycological relapse [3, 5, 28] . However, this study demonstrated that the mycological relapse rate 4 weeks after the last dose of posaconazole was lower than the rate 4 weeks after the last dose of fluconazole in the modified intent-to-treat subset (59.4% vs. 73.6%; P p ). The lower mycological relapse rate associated with po-.038 saconazole may prove to be beneficial, because the frequency of relapse observed among HIV-infected patients has been associated with both clinical and in vitro fluconazole resistance Downloaded from https://academic.oup.com/cid/article-abstract/42/8/1179/283108 by guest on 19 January 2019 [9] . In addition, there appears to be some evidence that Candida isolates may develop in vitro resistance during repeated episodes of oropharyngeal candidiasis and repeated therapy with fluconazole [29] . Despite the clinical relapse rate, there was no evidence of secondary resistance in the Candida species recovered during the mycological relapses. Encouraging in vitro results suggest that fluconazole-resistant Candida species remain susceptible to posaconazole, possibly because of differences in mechanisms of resistance [25, 30, 31] . In support of this premise, clinical trials have shown posaconazole to be effective in patients with advanced HIV infection and oropharyngeal or esophageal candidiasis due to organisms documented to be clinically and microbiologically resistant to fluconazole [32] . Consequently, posaconazole may become an important addition to the treatment armamentarium for oropharyngeal candidiasis.
Both posaconazole and fluconazole were generally well tolerated, and no clinically significant changes in laboratory results were observed in either treatment group. In subjects with invasive fungal infections, the most common adverse events associated with posaconazole salvage therapy were headache and gastrointestinal abnormalities (e.g., nausea and abdominal pain) [33] . Furthermore, posaconazole was well-tolerated during long-term administration, with no unique adverse events emerging over time [33] . Studies of healthy volunteers have shown that the safety profile of posaconazole does not appear to be influenced by age, race, or sex and that posaconazole has a low potential to prolong the QTc interval at plasma concentrations expected in the clinical setting [34, 35] .
The observations reported here indicate that oral posaconazole has a safety and tolerability profile and clinical efficacy rate similar to that of oral fluconazole at the same dosage and administration schedule in HIV-infected persons with oropharyngeal candidiasis. These results indicate that posaconazole may offer a beneficial alternative to other antifungal agents currently in clinical use for treating oropharyngeal candidiasis.
